We found 10 episodes of Oncology Today with Dr Neil Love with the tag “cancer”.
-
Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting: Chronic Lymphocytic Leukemia Edition
April 12th, 2023 | Season 1 | 1 hr 17 mins
cancer, cancer treatment, chemotherapy, dr neil love, immunotherapy, oncology, oncology education, research to practice
Featuring a discussion on chronic lymphocytic leukemia studies presented at ASH 2022 with Dr John Allan, moderated by Dr Neil Love.
-
Key Presentations in Hodgkin and Non-Hodgkin Lymphomas from the 2022 ASH Annual Meeting with Dr Matthew Lunning
March 2nd, 2023 | Season 1 | 1 hr 28 mins
cancer, cancer treatment, chemotherapy, dr neil love, immunotherapy, oncology, oncology education, research to practice
Featuring a discussion on lymphoma studies presented at ASH 2022, with Dr Matthew Lunning, moderated by Dr Neil Love.
-
Management of Desmoid Tumors with Dr Mrinal Gounder
February 28th, 2023 | Season 1 | 54 mins 17 secs
cancer, cancer treatment, chemotherapy, dr neil love, immunotherapy, oncology, oncology education, research to practice
Featuring a discussion on the management of desmoid tumors with Dr Mrinal Gounder, moderated by Dr Neil Love.
-
Management of HER2-Altered Non-Small Cell Lung Cancer
February 21st, 2023 | Season 1 | 1 hr 19 mins
cancer, cancer treatment, chemotherapy, dr neil love, immunotherapy, oncology, oncology education, research to practice
Featuring a discussion on targeted therapy for HER2-altered non-small cell lung cancer with Dr Bob Li, moderated by Dr Neil Love.
-
Management of Metastatic Non-Small Cell Lung Cancer without an Actionable Mutation
February 13th, 2023 | Season 1 | 49 mins 30 secs
cancer, cancer treatment, chemotherapy, dr neil love, immunotherapy, oncology, oncology education, research to practice
Featuring a discussion on new and emerging data in the management of NSCLC without an actionable mutation, with Dr Edward Garon, moderated by Dr Neil Love.
-
Key Presentations on Myeloproliferative Neoplasms from the 2022 ASH Annual Meeting — With Dr Srdan Verstovsek
February 9th, 2023 | Season 1 | 1 hr 19 mins
cancer, cancer treatment, chemotherapy, dr neil love, immunotherapy, oncology, oncology education, research to practice
Featuring a discussion on newly presented data with myelofibrosis, polycythemia vera and essential thrombocythemia with Dr Srdan Verstovsek, moderated by Dr Neil Love.
-
Advances in Diffuse Large B-Cell Lymphoma with Dr Gilles Salles
February 6th, 2023 | Season 1 | 43 mins 31 secs
cancer, cancer treatment, chemotherapy, dr neil love, immunotherapy, oncology, oncology education, research to practice
Featuring a discussion on recent data with targeted therapies for the treatment of diffuse large B-cell lymphoma with Dr Gilles Salles, moderated by Dr Neil Love.
-
Key Presentations in Acute Myeloid Leukemia and Myelodysplastic Syndromes from the 2022 ASH Annual Meeting with Dr Richard Stone
February 2nd, 2023 | Season 1 | 1 hr 10 mins
cancer, cancer treatment, chemotherapy, dr neil love, immunotherapy, oncology, oncology education, research to practice
Featuring a discussion on newly presented data in acute myeloid leukemia and myelodysplastic syndromes from the 2022 ASH Annual Meeting with Dr Richard Stone, moderated by Dr Neil Love.
-
Special Edition — Management of ER-Positive Breast Cancer with Drs Erica Mayer and Ruth O'Regan
January 31st, 2023 | Season 1 | 1 hr 39 mins
cancer, cancer treatment, chemotherapy, dr neil love, immunotherapy, oncology, oncology education, research to practice
Featuring a discussion on ER-positive breast cancer with Drs Erica Mayer and Ruth O’Regan, moderated by Dr Neil Love.
-
HER2-Positive Metastatic Breast Cancer with Professor Giuseppe Curigliano
January 26th, 2023 | Season 1 | 46 mins 57 secs
cancer, cancer treatment, chemotherapy, dr neil love, immunotherapy, oncology, oncology education, research to practice
Featuring a discussion of recent advances in the treatment of HER2-positive metastatic breast cancer with Professor Giuseppe Curigliano, moderated by Dr Neil Love.